Innoviva Company Profile (NASDAQ:INVA)

Analyst Ratings

Consensus Ratings for Innoviva (NASDAQ:INVA) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $11.20 (12.98% downside)

Analysts' Ratings History for Innoviva (NASDAQ:INVA)
Show:
DateFirmActionRatingPrice TargetActions
10/29/2015Robert W. BairdLower Price TargetNeutral$14.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/29/2015Cowen and CompanyLower Price TargetMarket Perform$15.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/5/2015Morgan StanleyReiterated RatingOverweight$7.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015Sanford C. BernsteinReiterated RatingMarket Perform$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Bank of America Corp.DowngradeBuy -> Neutral$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2014Leerink SwannDowngradeOutperform -> Market Perform$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2014 forward)

Earnings

Earnings History for Innoviva (NASDAQ:INVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
10/26/2016        
7/28/2016Q216$0.11$0.17$31.13 million$32.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q2($0.06)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.08)($0.09)$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414($0.15)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.14)($0.19)$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.44)($0.57)$4.39 million$0.93 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$1.02$0.93ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Innoviva (NASDAQ:INVA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Current Dividend Information for Innoviva (NASDAQ:INVA)
Annual Dividend:$0.25
Dividend Yield:1.94%
Payout Ratio:147.07% (Based on Trailing 12 Months of Earnings)
38.46% (Based on Current Year Consensus EPS Estimate)
21.19% (Based on Next Year Consensus EPS Estimate)

Dividend History for Innoviva (NASDAQ:INVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
7/30/2015quarterly$0.257.01%9/8/20159/10/20159/30/2015Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015quarterly$0.256.43%6/10/20156/12/20156/30/2015Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015quarterly$0.255.85%3/10/20153/12/20153/31/2015Tweet This Announcement  Share This Announcement on StockTwits
10/31/2014quarterly$0.256.24%11/21/201411/25/201412/23/2014Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014quarterly$0.258/26/20148/28/20149/18/2014Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Innoviva (NASDAQ:INVA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/18/2016James L TyreeDirectorSell813$10.47$8,512.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Innoviva (NASDAQ:INVA)
DateHeadline
07/29/16 03:20 PMEdited Transcript of INVA earnings conference call or presentation 28-Jul-16 9:00pm GMT -
07/29/16 07:37 AMInnoviva Reports Second Quarter 2016 Financial Results - Business Wire (press release)
07/28/16 05:34 PMInnoviva beats 2Q profit forecasts - [AP] - The South San Francisco, California-based company said it had net income of 13 cents per share. Earnings, adjusted for amortization costs and stock option expense, were 17 cents per share. The results ...
07/28/16 03:17 PM4:17 pm Innoviva reports EPS in-line, beats on revs -
07/28/16 03:14 PMINNOVIVA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
07/28/16 03:05 PMInnoviva Reports Second Quarter 2016 Financial Results - [Business Wire] - Innoviva, Inc. today reported financial results for the second quarter ended June 30, 2016. Royalties earned on net sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® from Glaxo Group Limited during the second quarter of 2016 were $35.7 million, up from $13.9 million in the second quarter of 2015.
07/28/16 07:41 AMVertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short - Nasdaq
07/28/16 07:02 AMAmgen (AMGN) Tops Q2 Earnings & Revenues, Raises View -
07/28/16 06:07 AMQ2 2016 Innoviva Inc Earnings Release - After Market Close -
07/27/16 07:28 AMInnoviva, Inc. (NASDAQ:INVA) To Report June 2016 Results - The Voice Registrar
07/26/16 03:55 PMAfter GILD Earnings, Which Biomed Stock is Best Right Now? -
07/26/16 07:37 AMNotable Monday Option Activity: CAVM, INVA, BWLD - Nasdaq
07/26/16 07:36 AMShould You Buy Innoviva (INVA) Ahead of Earnings? -
07/24/16 04:20 PMActelion (ALIOF) Beats Q2 Earnings & Revenues, View Up - Nasdaq
07/23/16 08:40 AMSynta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus
07/22/16 04:36 PMAegerion to Withdraw Juxtapid from EU, Reduces Workforce - Nasdaq
07/22/16 04:36 PMEarnings Quick View: Centene Corporation (NYSE:CNC), Terreno Realty Corporation (NYSE:TRNO), Globant S.A. ... - Engelwood Daily
07/22/16 04:36 PMSynta (SNTA) Cuts Q2 Loss Y/Y, Madrigal Merger in Focus - Yahoo Finance
07/22/16 04:36 PMInnoviva, Inc. (NASDAQ:INVA) Upcoming Earnings: What matter for investors? - The Voice Registrar
07/21/16 10:42 AMBiogen (BIIB) Stock Up on Q2 Earnings Beat, Raised Outlook
07/20/16 03:05 PMInnoviva to Report Second Quarter 2016 Financial Results on July 28 at 5:00 p.m. EDT - [Business Wire] - Innoviva, Inc. announced today that it will report financial results for the second quarter ended June 30, 2016 after market close on Thursday July 28, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m.
07/20/16 02:41 PMCelgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma - Nasdaq
07/20/16 02:41 PMAstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint - Yahoo Finance
07/20/16 07:40 AMEvoke (EVOK) Stock Down on Poor Phase III EVK-001 Data - Nasdaq
07/20/16 07:40 AMBristol-Myers' Opdivo Label Expansion Under U.S., EU Review - Nasdaq
07/20/16 07:40 AMAstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint - Nasdaq
07/18/16 09:55 AMZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
07/14/16 04:49 PMEli Lilly, Boehringer Collaborate for Metastatic Breast Cancer
07/14/16 08:11 AMWhat's Propelling Innoviva Inc to Increase So Much? - Consumer Eagle
07/13/16 07:35 AMCytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data - Nasdaq
07/13/16 07:35 AMStock Providing Gains on the Month for Investors: Innoviva, Inc. (:INVA) - Telanagana Press
07/12/16 04:55 PMGilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval - Yahoo Finance
07/12/16 04:55 PMLigand (LGND) Signs Deal with Gilead for OmniAb Technology - Yahoo Finance
07/12/16 04:55 PMSeth Klarman Buys —5 Million Shares of Cascadian Therapeutics - GuruFocus.com
07/12/16 04:55 PMAbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S. - Nasdaq
07/12/16 09:02 AMAbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
07/11/16 09:21 AMLigand (LGND) Signs Deal with Gilead for OmniAb Technology
07/08/16 07:34 AMMerrimack Stock Up on Fast Track Status for Seribantumab - Yahoo Finance
07/07/16 04:45 PMSanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan - Yahoo Finance
07/07/16 07:08 AMInnoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : July 7, 2016 -
07/06/16 09:20 AMStock Tracking Down This Month; Investor Alert on Innoviva, Inc. (:INVA) - Engelwood Daily
07/05/16 09:15 AMInnoviva Inc Stock Is Rising Now - Press Telegraph
06/29/16 07:30 AMNoteworthy Tuesday Option Activity: VMW, INVA, KONA - Nasdaq
06/28/16 04:37 PMNoteworthy Tuesday Option Activity: VMW, INVA, KONA
06/25/16 04:21 PMStock Tracing Lower on the Week Innoviva, Inc. (:INVA) - Engelwood Daily
06/21/16 04:22 PMGlaxoSmithKline COPD Triple Combination Study Shows Improved Lung Function Vs Rival
06/21/16 04:22 PMGlaxo/Innoviva's Closed Triple Combination Tops Phase III
06/21/16 09:12 AMGSK FULFILS Goals, CDXC Sinks On Short Seller Report, LPTN Up On Defense Grant - Nasdaq
06/20/16 08:16 PMBRIEF-Theravance Biopharma highlights positive results from phase 3 fulfil study of closed triple announced by Glaxosmithkline, Innoviva - * Highlights positive top-line results from pivotal phase 3 fulfil study of closed triple announced by Glaxosmithkline, Innoviva
06/20/16 04:29 PMGSK triple combo study shows better lung function - MarketWatch

Social

About Innoviva

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INVA
  • CUSIP: 88338T10
Key Metrics:
  • Previous Close: $12.87
  • 50 Day Moving Average: $11.30
  • 200 Day Moving Average: $11.50
  • P/E Ratio: 78.00
  • P/E Growth: 0.30
  • Market Cap: $1.43B
  • Beta: 1.64
  • Current Year EPS Consensus Estimate: $0.65 EPS
  • Next Year EPS Consensus Estimate: $1.18 EPS
Additional Links:
Innoviva (NASDAQ:INVA) Chart for Sunday, July, 31, 2016